Despite advances in control via snail eradication and large-scale chemotherapy using praziquental, schistosomiasis continues to spread to new geographic areas particularly in sub-Saharan Africa. Presently, there is no vaccine for controlling this disease. We have concentrated on a functionally important schistosome antigen Sm-p80 as a possible vaccine candidate for schistosomiasis. Here we report the proliferation of spleen cells in response to the recombinant Sm-p80 protein and cytokine (IFN-γ and IL-4) production by the splenocytes. These spleen cells were obtained from groups of mice that were vaccinated with a DNA vaccine formulation containing Sm-p80 and one of the Th-1 (IL-2 or IL-12) or Th-2 (GM-CSF, IL-4) enhancer cytokines. The splenocytes from the groups of mice vaccinated with Sm-p80 DNA in the presence of Th-2 enhancer cytokines showed moderate but detectable proliferation. The splenocytes obtained from mice vaccinated with Sm-p80 DNA with Th-1 enhancer cytokines IL-2 and IL-12 provided the highest proliferation. The IFN-γ production by splenocytes was found to follow the similar pattern [(Sm-p80) < (Sm-p80 + IL-4) < (Sm-p80 + GM-CSF) < (Sm-p80 + IL-12) < (Sm-p80 + IL-2)], as has been observed for the proliferation and protection data. However, the elevated IL-4 production was inversely correlated to Sm-p80-induced splenocyte proliferation or the protection. These results show again that protective immune response induced by Sm-p80 is of Th-1 type. 
Résumé : CARACTÉRISATION D'UNE PROTECTION IMMUNITAIRE CONTRE SCHISTOSOMA MANSONI INDUITE PAR L'ADN AVEC LA SOUS-UNITÉ SM-P80 ASSOCIÉE À DIVERS ADJUVANTS

Malgré les progrès dans son contrôle par les campagnes d'éradication de mollusques et de chimiothérapie par le praziquantel à grande échelle, la schistosomiase continue de toucher de nouvelles zones géographiques, notamment en Afrique sub-saharienne. Aucun vaccin n'est disponible actuellement pour contrôler la maladie. Nous nous sommes intéressés à l'importante activité antigénique de la protéine Sm-p80 en tant que candidat potentiel à une vaccination contre la schistosomiase. Nous rapportons ici la prolifération des cellules spléniques en réponse à la protéine recombinante Sm-p80, et la production de cytokines (IFN-γ et IL-4) par les splénocytes. Ces cellules spléniques ont été obtenues chez des groupes de souris vaccinées par une formulation à base d'ADN composée de Sm-p80 et de cytokines Th-1 (IL-2 ou IL-12) ou Th-2 (GM-CSF, IL-4). On observe une prolifération modérée, mais décelable, des splénocytes du groupe des souris vaccinées par Sm-p80 en présence de cytokines Th-2, et une plus importante prolifération des splénocytes des souris vaccinées par Sm-p80 en présence de cytokines Th-1 (IL-2 et IL-12). La production d'IFN-γ par les splénocytes a suivi le même modèle [(Sm-p80) < (Sm-p80 + IL-4) < (Sm-p80 + GM-CSF) < (Sm-p80 + IL-12) < (Sm-p80 + IL-2)] que ce qui a été constaté
However, a major problem that has hindered schistosomiasis vaccine research and development concerns the identification and selection of potential protective antigens encoded by the parasite. Recent studies have amplified these concerns (Hagan & Sharaf, 2003) . Independent examination of the six "priority antigens" (paramyosin, glutathione S-transferase, fatty acid binding 14 kDa protein, IrV-5, triose phosphate isomerase and Sm23) via a standard comparative World Health Organization delineated procedure, resulted in none of them providing the stated goal of 40 % protection or better (Bergquist et al., 2002) . This report highlights the continued and urgent need for an examination and assessment of additional schistosomiasis vaccine candidates.
INTRODUCTION
I t is widely believed that a schistosomiasis vaccine would make an enormous contribution to current methods of control, particularly if it provides a potent, long-lasting immunity to the disease (Capron et al., 2002; Pearce, 2003; Hagan & Sharaf, 2003) .
We have identified a novel schistosome protein that was originally identified to be involved in the surface membrane biogenesis (Siddiqui et al., 1993) . This phenomenon has been considered to be one of the mechanisms utilized by blood-dwelling helminths to evade the protective host immune response (Podesta et al., 1987; Siddiqui et al., 1993) . This protein designated calpain, has two subunits, the larger of which, called has been demonstrated to protect up to 60 % against cercarial challenge when administered to mice in a DNA vaccine formulation (Siddiqui et al., 2003a, b) . In the present study, we report the in vitro proliferation of splenocytes in response to the recombinant Smp80 protein as well as cytokine production by these cells. These splenocytes were obtained from groups of mice that were vaccinated with a DNA vaccine formulation containing Sm-p80 and one of the Th-1 (IL-2 or IL-12) or Th-2 (GM-CSF, IL-4) enhancer cytokines.
MATERIALS AND METHODS
IMMUNIZATION PROTOCOLS
A s described earlier (Siddiqui et al., 2003 a, b) , to determine the protective effect of the large subunit of S. mansoni calpain, each mouse (C57BL/6 mice, 3-4 weeks old, 10-12 g) was primed with 100 µg Sm-p80-pcDNA3. First and second boosts (100 µg Sm-p80-pcDNA3 each time) were given at 4 and 8 weeks, respectively. Each mouse in the control group received 100 µg pcDNA3 on day 1, followed by two injections of 100 µg each, at week 4 and 8, as above. Similar immunization regimen was also followed to test the adjuvant effects of GM-CSF, IL-4, IL-2 and IL-12. Briefly, each mouse in the "cytokine group" received 100 µg pORF-mGM-CSF or pORFmIL-4 or pORF-mIL-2 or pORF-mIL-12 and 100 µg Smp80-pcDNA3 on day 1, and two boosters of the exact same concentration and composition, 4 weeks part, as above. The control mice of the "cytokine group" received only100 µg pcDNA3. Four weeks after, the second boost, all of the mice from the groups outlined above, were challenged with 150 cercariae. The mice were sacrificed six weeks after challenge; adult worms were recovered from each mouse and percent reduction in worm burdens in vaccinated verses control animals was calculated (Siddiqui et al., 2003a, b) . Each group of mice contained at least 15 animals.
SPLENOCYTE PROLIFERATION ASSAYS
The spleens from the five groups of mice, outlined above, were processed as follows: each spleen was removed aseptically then meshed through a fine screen in 6 ml of RPMI 1640 medium (Invitrogen Corporation, Carlsbad, CA) containing 10 % fetal bovine serum (FBS). The splenocytes were collected via centrifugation at 1,000 × g for 15 min. The resultant pellet was then resuspended in 1 ml Opti-Freeze DMSO Cryopreservation Medium (Fisher Scientific, Hampton, NH), placed in -85 o C overnight and finally stored at -135 o C until used. The day of assay, the cells were thawed, washed in 9 ml of RPMI 1640 medium containing 10 % FBS and the cells were collected by centrifugation at 1,000 × g for 15 min and the final pellet was resuspended in the medium. The viability of cells was determined via Trypan Blue, > 80 % of cells were found to be viable. In a 96-well flat-bottom plate, the splenocytes (5 × 10 5 cells/100 µl/well) were stimulated with baculovirus generated Sm-p80 recombinant protein (1.2 µg/ 100 µl/well) (Siddiqui et al., 2003a) . ConA was used at a concentration of 0.1 µg/well. All assays were performed in triplicate wells. The plates were incubated at 37 o C in 5 % CO 2 -humidified incubator. After 24 h incubation, 20 µl of AlamarBlue (AB) reagent [(BioSource International, Camarillo, CA) (Ahmed et al., 1994) ] was added and the plates were incubated again as above for up to 72 hrs. The plates were read at 24, 48 and 72 hrs at 570 nm and 630 nm. The reduction of AB was monitored spectrophotometrically according to the manufacturer's instructions and the reduction was expressed as a percentage (% reduced). Briefly, the calculation of % reduced is as follows when the samples are read at: λ1 = 570 nm, 82 = 600 nm.
Where: (ε red λ1) = 155,677 (Molar extinction coefficient of reduced AB at 570 nm); (ε red λ2) = 14,652 (Molar extinction coefficient of reduced AB at 600 nm); (ε ox λ1) = 80,586 (Molar extinction coefficient of oxidized AB at 570 nm); (ε ox λ2) = 117,216 (Molar extinction coefficient of oxidized AB at 600 nm); (Aλ1) = Absorbance of test wells at 570 nm; (Aλ2) = Absorbance of test wells at 600 nm; (A´λ1) = Absorbance of negative control wells which contain medium plus AB but to which no cells have been added at 570 nm; (A´λ2) = Absorbance of negative control wells which contain medium plus AB but to which no cells have been added at 600 nm.
ESTIMATION OF CYTOKINE PRODUCTION BY PROLIFERATING SPLENOCYTES
To quantify the cytokine production by the proliferating splenocytes, exact duplicate wells were run simul-SIDDIQUI A.A., PINKSTON J.R., QUINLIN M.L. ET AL.
taneously, as described above. After 48 hrs of incubation, the medium was collected from each well and stored at -70 o C. Productions of cytokines by proliferating splenocytes was determined via BD OptEIA ELISA kits for mouse IL-4 and mouse IFN-γ (BD Biosciences Pharmingen, San Diego, CA), according to the manufacturer's instructions.
STATISTICAL ANALYSIS
Comparisons of cellular immune responses among groups of mice were performed by two-tailed t test for two groups of animals or by analysis of variance (ANOVA) for more than two groups. Bonferroni adjustments were included for multiple comparisons, to reduce the risk of reaching false conclusions based on chance. In all cases, P values < 0.05 were considered significant.
RESULTS AND DISCUSSION
I n this study we have determined the proliferative responses and production of cytokines via Alamar Blue assays (Ahmed et al., 1994) using frozen spleen cells (Wright et al., 2002) from five groups of mice. The groups of mice used in this study were vaccinated with a DNA vaccine formulation as described earlier (Siddiqui et al., 2003a, b) and were as follows: Group 1 (Sm-p80-pcDNA3), Group 2 (Sm-p80-pcDNA 3 + pORFmGM-CSF), Group 3 (Sm-p80-pcDNA3 + pORF-mIL-4), Group 4 (Sm-p80-pcDNA3 + pORF-mIL-12) and Group 5 (Sm-p80-pcDNA3 + pORF-mIL-2). The splenocytes from the vaccinated groups proliferated significantly higher than compared to their respective controls when stimulated in vitro with Sm-p80 protein (Figs 1-3) . However, Sm-p80 driven proliferation of splenocytes was markedly lower when compared to the stimulation induced by ConA (Figs 1-3) . The splenocytes from the groups of mice vaccinated with Sm-p80 DNA in the presence of Th-2 enhancer cytokines showed moderate but detectable proliferation (Fig. 2) . The splenocytes obtained from mice vaccinated with Sm-p80 DNA with Th-1 enhancer cytokines IL-2 and IL-12 provided the highest proliferation (Fig. 3) . Specifically, the splenocytes from the Sm-p80-pcDNA vaccinated group exhibited a 12 % higher proliferation compared to their controls (P < 0.001) (Fig. 1) . The introduction of GM-CSF and IL-4 in the DNA vaccine formulation increased this proliferation by splenocytes to 17 % (P < 0.001) and 16 % (P < 0.001), respectively (Fig. 2) . As shown in Fig. 3 , the highest degree of splenocyte proliferation was observed in the IL-12 group [21 % (P < 0.001)] and IL-2 group [23 % (P < 0.001)]. The splenocyte proliferation was found to follow the similar pattern [(Sm-p80) < (Sm-p80 + IL-4) < (Sm-p80 + GM-CSF) < (Sm-p80 
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+ IL-12) < (Sm-p80 + IL-2), as has been observed for the protection data (Siddiqui et al., 2003a, b) . Briefly, Sm-p80 by itself provided a 39 % protection against challenge infection in C57BL/6 mice (Siddiqui et al., 2003a, b) . Co-injection of plasmid DNA encoding IL-4 with Sm-p80 DNA yielded a protection level of 42 % (Siddiqui et al., 2003b) . The protection was found to be 44 % when plasmid encoding GM-CSF was co-administered with Sm-p80 DNA (Siddiqui et al., 2003a) . Coinjection of plasmid DNA encoding IL-12 with Sm-p80 DNA yielded a protection level of 45 % (Siddiqui et al., 2003b) . This protection was increased to 57 % when plasmid DNA encoding IL-2 was co-administered with Sm-p80 DNA (Siddiqui et al., 2003b) . As shown in Table I , the degree of proliferation was also correlated by the IFN-γ production. The IFN-γ production by splenocytes was found to follow the similar trend [(Sm-p80) < (Sm-p80 + IL-4) < (Sm-p80 + GM-CSF) < (Sm-p80 + IL-12) < (Sm-p80 + IL-2), as has been observed for the proliferation and protection data (Siddiqui et al., 2003a, b) . Conversely, the elevated IL-4 production ( Table I) did not positively influence either the splenocyte proliferation or the protection. Both the splenocyte proliferation profiles and the cytokine production data are in agreement with our previous findings in which immunization with Sm-p80 alone resulted in the elevation of IgG 2A and IgG 2B titers, a clear indication that a predominantly Th-1 type of antibody response was induced by this antigen (Siddiqui et al., 2003b) . This inclination towards a Th-1 type response following intramuscular injections of plasmid DNA is now widely accepted as an important characteristic of naked DNA vaccinations (Min et al., 2002) . Furthermore, co-inoculation of Sm-p80 with GM-CSF resulted in augmentation of total IgG and IgG 1 antibody titers, indicating that Th-2 arm of the immune system was also induced. Interestingly, however, IgG 2A titers remained high but IgG 2B titers were reduced (Siddiqui et al., 2003a) . Elevation of IgG 2A titers suggested that either GM-CSF was unable to counter the already biased Th-1 type response induced by intramuscular injections of plasmid DNA containing Th-1 promoting Sm-p80-pcDNA3 415 ± 27.9 171 ± 23.2 Sm-p80-pcDNA3 + pORF-mGM-CSF 488 ± 37.9 134 ± 12.1 Sm-p80-pcDNA3 + pORF-mIL-4 400 ± 38.1 245 ± 13.6 Sm-p80-pcDNA3 + pORF-mIL-12 1,071 ± 54.3 43 ± 2.3 Sm-p80-pcDNA3 + pORF-mIL-2 1,415 ± 122.9 46 ± 1.5 et al., 2003b) . Furthermore, introduction of plasmid DNA encoding IL-12 with Sm-p80 augmented only total IgG and IgG 2A titers when compared with Sm-p80 alone group (Siddiqui et al., 2003b) . Taken together, data obtained in this study reinforces our pervious findings (Siddiqui et al., 2003a, b) , on antibody titers and induction Th-1 type response by Sm-p80. In summary, our results with Sm-p80 and of others with another schistosome antigen Sm23 (Da'Dara et al., 2003) , it is becoming evident that to achieve good protection against cercarial challenge, a dominant Th-1 type of response is required, at least in the murine model. The efficacy of both of these antigens is greatly reduced when using protocols that diminish Th-1 type of response (Siddiqui et al., 2003; Da'Dara et al., 2000a, b; . As per the WHO-TDR recommendations (> 50 % consistent protection in mice) Sm-p80 is now ready to be taken into human phase I trials, but we strongly believe that this or any other schistosome antigen should not be rushed pre-maturely as has been the case with other "priority antigens". Therefore, we are presently testing the protective and therapeutic potential of Sm-p80 in non-human primates. Furthermore, studies are also underway to test the vaccine effect of Smp80, using different strains of mice to detect a potential "host genetic effect" on the level of protection
